Potential Therapeutic Targets of the Endocannabinoid System in Common Neurodegenerative Disorders and Organic Acidemias

Abstract

The cannabinoid chemistry is currently being addressed in preclinical approaches as a viable therapeutic alternative for the management of a wide range of signs, symptoms, and some biochemical hallmarks of many neurological pathologies (such as neuroinflammation and neurodegeneration). This clinical orientation is grounded on the consistent promissory profile that cannabinoid compounds have shown, and the great necessity of feasible options to undergo such disorders. Even though at early research stages, metabolic disorders are starting to rise as potential targets of cannabinoid alternatives; approaches in this term could, in turn, aim to modulate the endocannabinoid response for therapeutic purposes. This review recalls the pathologic scenarios endured in the course of neurological diseases of high occurrence and the most typical metabolic disorders, while discussing the neuroprotective mechanisms of cannabinoid agonists in the central nervous system, and the potential targets of the endocannabinoid system and metabolic disorders.

Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

“…The endocannabinoid system (ECS) has been recognized for its therapeutic role for the past two decades. It consists of receptors, ligands, and associated molecules, altogether playing an essential role in physiological and pathological conditions (Aguilera & Santamaria, 2017; Gómez‐Ruiz et al., 2007; Reggio, 2010). Its function is implicated in physiological processes like nociception, appetite, lipid metabolism, gastrointestinal motility, cardiovascular modulation, pain sensation, motor activity, mood, and memory (Di Marzo, 2018; Kunos et al., 2000; Lichtman, 2000; Pertwee, 2001; Zogopoulos et al., 2013a).…”